The role of the clinical immunology laboratory in the diagnosis and monitoring of connective tissue diseases

Saudi Medical Journal

Volumn 25, Issue 12, 2004, Pages 1796-1807

  Aziz, Khalil A ^a   Faizal, Abdul A ^a  

^a BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; AZATHIOPRINE; CARDIOLIPIN ANTIBODY; CELL NUCLEUS ANTIGEN; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; CRYOGLOBULIN; CYCLOPHOSPHAMIDE; DNA ANTIBODY; DNA TOPOISOMERASE; DOUBLE STRANDED DNA; HISTONE; HISTONE ANTIBODY; IMMUNOGLOBULIN A; IMMUNOGLOBULIN CLASS; IMMUNOGLOBULIN D; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LA ANTIBODY; LACTOFERRIN; LYSOSOME ENZYME; MYELOPEROXIDASE; NEUTROPHIL CYTOPLASMIC ANTIBODY; RHEUMATOID FACTOR; RIBONUCLEOPROTEIN ANTIBODY; RO ANTIBODY; SCL 70 ANTIBODY; SM ANTIBODY; UNINDEXED DRUG;

ANTIBODY DETECTION; ANTIBODY SCREENING; AUTOIMMUNE DISEASE; CLINICAL FEATURE; CLINICAL IMMUNOLOGY; COMPLEMENT BLOOD LEVEL; CONNECTIVE TISSUE DISEASE; COUNTER IMMUNOELECTROPHORESIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; EARLY DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HEALTH CARE COST; HUMAN; IMMUNE DEFICIENCY; IMMUNODIFFUSION; IMMUNOFLUORESCENCE TEST; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOLOGICAL MONITORING; IMMUNOSUPPRESSIVE TREATMENT; LABORATORY DIAGNOSIS; LABORATORY TEST; METHODOLOGY; MIXED CONNECTIVE TISSUE DISEASE; QUALITATIVE DIAGNOSIS; QUANTITATIVE ASSAY; REVIEW; SEROLOGY; SOCIOECONOMICS; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANTIBODIES, ANTINUCLEAR; AUTOANTIBODIES; AUTOIMMUNE DISEASES; CONNECTIVE TISSUE DISEASES; COST-BENEFIT ANALYSIS; DIAGNOSTIC ERRORS; FOLLOW-UP STUDIES; HEALTH RESOURCES; HUMANS; IMMUNOLOGIC TESTS; LABORATORY TECHNIQUES AND PROCEDURES; PREDICTIVE VALUE OF TESTS; SAUDI ARABIA;

EID: 13844276992     PISSN: 03795284     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (82)

1. Kumar P, Clark M. Clinical Medicine. 5th ed. Edinburgh: WB Saunders; 2002. p. 511-586.
2. Shmerling RH, Fuches HA, Lorish CD, Nichols LA, Partridge AJ, Brigham RB et al. Guidelines for the initial evaluation of the adult patients with acute musculoskeletal symptoms. Arthritis Rheum 1996; 39: 1-8.
3. Chapel H, Haeney M, Misbah S, Snowden N. Clinical Immunology. 4th ed. Blackwell Science 1999. p. 183-205.
4. Swaak AJ, Huysen V, Smeenk RJ. Antinuclear antibodies in routine analysis: the relevance of putative clinical association. Ann Rheum Dis 1993; 52: 110-114.
5. Hollingsworth PN, Pummer SC, Dawkins RL. Antinuclear antibodies. In: Peter PN, Shoenfield Y, editors. Autoantibodies. Elsevier Science B V; 1996. p. 74-90.
6. White RH, Robbins DL. Clinical significance and interpretation of antinuclear antibodies. West J Med 1987; 147: 210-213.
7. Osterland CK. Laboratory diagnosis and monitoring in chronic systemic autoimmune diseases. Clin Chem 1994; 40: 2146-2154.
8. Feltkamp TEW, Klein F, Janssens MB. Standardization of the quantitative determination of antinuclear antibodies (ANAs) with a homogenous pattern. Ann Rheum Dis 1988; 47: 906-909.
9. Tan TE. Antinuclear antibodies: diagnostic markers for autoimmune disease and probes for cell biology. Adv Immunol 1989; 44: 93-151.
10. Takahashi M, Okada J, Kondo H. Six cases positive for anti-centromere antibodies with ulcer and gangrene in extremities. Br J Rheumatol 1997; 36: 889-893.
11. Fritzler MJ, Kinsella TD. The CREST syndrome: a distinct serological entity with anticentromere antibodies. Am J Med 1980; 69: 520-526.
12. Reimer G, Steen VM, Penning CA. Correlates between autoantibodies to nucleolar antigen and clinical features in patients with systemic sclerosis (Scleroderma). Arthritis Rheum 1988; 31: 525-532.
13. Hamburger HA. Cascade testing for autoantibodies in connective tissue diseases. Mayo Clin Proc 1995; 70: 183-184.
14. Kozin F, Fowler M, Koethe SM. A comparison of the sensitivities and specificities of different substrate for the fluorescent anti-nuclear antibody test. Am J Clin Pathol 1980; 74: 785-790.
15. Kern P, Kron M, Hiesche K. Measurement of antinuclear antibodies: Assessment of different system. Clin Diag Lab Immunol 2000; 7: 72-78.
16. Aziz KA. Ineffectiveness of rat liver tissues in the diagnosis of connective tissue diseases. Saudi Med J 2004; 25: 442-446.
17. Hormon CE, Deng J, Peebles CL, Tan EM. The importance of tissue substrate in the SS-A/Ro antigen-antibody system. Arth Rheum 1984; 27: 166-173.
18. Du L, Fukushima S, Sallmyr A, Manthorpe R, Bredberg A. Exposure of Hep-2 cells to stress condition influences antinuclear antibody reactivity. Clin Diag Lab Immunol 2002; 9: 287-294.
19. Juby AG, Davies P, McElhaney JE, Gravenstein S. Prevalence of selected autoantibodies in different elderly subpopulations. Br J Rheum 1994; 33: 1121-1124.
20. Hamburger M, Hodes S, Barland P. The incidence and clinical significance of antibodies to the extractable nuclear antigens. Am J Med Sci 1977; 273: 21-28.
21. Nishikai M, Reechlin M Heterogeneity of precipitating antibodies in polymyositis and dermatomyositis: characterization of Jo-1 antibody system. Arth Rheum 1980; 23: 881-888.
22. Phan TG, Wong RCCW, Adelstein S. Autoantibodies to extractable nuclear antigens: making detection and interpretation more meaningful. Clin Diag Lab Immunol 2002; 9: 1-7.
23. Rondeel JM, Gelder WV, Leeden HVD. Different strategies in the laboratory diagnosis of autoimmune disease: immunofluorescence, enzyme-linked immunosorbent assay or both? Ann Clin Biochem 1999; 36:189-195.
24. Lock JR. Unsworth DJ. Antibodies to extractable nuclear antigens. Has technological drift affected clinical interpretation? J Clin Pathol 54: 187-190.
25. Maddison PJ, Skinner RP, Valachyiannapoulos P. Antibodies to nRNP, Sm, Ro (SSA) and La (SSB) detected by ELISA: their specificity and inter-relations in connective tissue disease sera. Clin Exp Immunol 1985; 62: 337-345.
26. Meilof JF, Bantjes I, De Jong J. The detection of anti-Ro/SSA and anti-La/SSB antibodies. Comparison of counter immunoelectrophoresis with immunoblot, ELISA, and RNA precipitation assays. J Immunol Methods 1990; 133: 215-226.
27. James K, Meek G. Evaluation of commercial enzyme immuno assays compared to immunofluorescence and double diffusion for antibodies associated with autoimmune disease. Am J Clin Path 1992; 97: 559-565.
28. Monce NM, Bogusky RT, Cappel NN. An enzyme immunoassay screening test for the detection of total antinuclear antibodies. J Clin Lab Ana 1991; 5: 439-442.
29. van Venrooij WJ, Charles P, Maini. The consensus workshops for the detection of autoantibodies to intracellular antigens in rheumatic disease. J Immunol Methods 1991; 140: 181-189.
30. Ward AM, Wild GD, Riches PG, Sheldon J. PRU handbook of autoimmunity, PRU publications 2001. p. 89-134.
31. Wharen M, Tengner P, Gunnarson I, Lundberg I, Hedfors E, Ringertz NR et al. Ro/SSA and La/SSB antibody level variation in patients with Sjogren's syndrome and systemic lupus erythematosus. J Immunol 1998; 11: 29-38.
32. Sissa M, Amital-Teplizki H, Haim N, Cohen Y, Shoenfeld Y. Autoantibodies in neoplasia. An unresolved enigma. Cancer 1990; 65: 2554-2558.
33. Davidson BKS, Kelly CA, Griffiths ID. Primary Sjogren's syndrome in the north of England: a long-term follow up. Rheum 1999; 38: 245-253.
34. James JA, Dicky DJD, Fujsaku A. Antigenicity of recombinant Ro (SS-A) fusion protein. Arth Rheum 1990; 33: 102-106.
35. Sontheimer RD, Madisson PJ, Reichlin M, Jorden RE, Stasthy P, Gilliam JN. Serological and HAL associations in subacute cutaneous lupus erythematosus. Ann Intern Med 1982; 97: 664-671.
36. Singsen BH, Akhter JE, Weinstein MM, Sharp GC. Congenital complete heart block and SSA antibodies: obstetric complications. Am J Obstet Gynecol 1985; 512: 665-669.
37. Marvragani CP, Dafni UG, Tzioufas AG, Moutsopoulos HM. Pregnancy outcome and anti-Ro/SSA in autoimmune disease: a retrospective cohort study. Br J Rheum 1998; 37: 740-745.
38. Holyst MM, Hoffman RW. U-small nuclear ribonucleoprotein (RNP) reactive autoantibodies: Diagnostic test and clinical interpretation. Clin Immunol Let 1998; 18: 53-57.
39. Panush RS, Edwards NG, Longley S, Webster E. Rhupus syndrome. Arch Intern Med 1988; 148: 1633-1636.
40. Foster HE, Malleston PN, Petty RE, Cabral DA. Anti-RNP antibody in a child with undifferentiated carcinoma and no evidence of mixed connective tissue disease. Br J Rheum 1997; 36: 289-291.
41. Arnett FC, Hamilton RG, Roebber MG. Increased frequency of Sm and nRNP autoantibodies in American blacks compared to whites with systemic lupus erythematosus. J Rheum 1988; 15: 1773-1776.
42. ter Borg EJ, Groen H, Horst G. Clinical association of anti-ribonucleoprotein antibodies in patients with systemic lupus erythematosus. Sem Arth Rheum 1990; 20: 164-173.
43. Worrall J, Snaith ML, Batchelor R, Isenberg DA. SLE-rheumatological view. Q J Med 1990; 275: 319-330.
44. Jacobsen S, Halgerg P, Ullman S, Van Verooj WJ, Hoier-Madsen M, Wjik A. Clinical features and serum anti-nuclear antibodies in 230 Danish patients with systemic sclerosis. Br J Rhuem 1998; 37: 39-45.
45. Bernstein RM, Morgan SH, Chapman J. Anti-Jo-1 antibody: a marker for myositis with interstitial lung disease. B M J 1984; 289: 151-152.
46. Marguerie C, Bunn CC, Byeynon HL, Bernstein RM, Highes JM, So AK. Polymositis, pulmonary fibrosis and autoantibodies to aminoacyl-tRNA synthetase enzyme. Q J Med 1990; 77: 1019-1038.
47. Rubin RL, Waga S. Antihistone antibodies in systemic lupus erythematosus. J Rheum 1987; 14 (Suppl 13): 118-126.
48. Spickett G. Oxford Handbook of Clinical Immunology. Oxford (UK): Oxford University Press; 1999.
49. Barbas SM, Ditzel HJ, Salonen EM, Wang WP, Sliverman GJ, Burton DR. Human antibody recognition of DNA. Proc Natl Acad Sci USA 1995; 92: 2529-2533.
50. Swaak T, Smeenk RJ. Detection of anti-dsDNA as a diagnostic tool: a prospective study in 441 non systemic lupus erythematosus patients with anti-dsDNA antibody (anti-dsDNA). Annal Rheum Dis 1985; 44: 245-251.
51. ter Borg EJ, Horst G, Hummell EJ. Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. A long term prospective study. Arth Rheum 1990; 33: 634-643.
52. Davis P, Christian B, Russell AS. Immunofluorescence technique for the detection of antibodies to n-DNA: comparison with radioimmunoassay. J Rheum 1977; 4: 14-20.
53. Arnett FC, Edworthy SM, Bloch DA, Mcshane DJ, Fries JF, Cooper NS et al. The American rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis. Arth Rheum 1988; 88: 315-324.
54. Saraux A, Guedes C, Allain A, Baron D, Youinou P, Le Goff P. From classification criteria to diagnostic criteria for rheumatoid arthritis. Rev Rheum 1996; 63: 159-161.
55. Sinclair D, Hull RG. Why do general practitioners request rheumatoid factor? A study of symptoms, requesting patterns and patients outcome. Ann Clin Biochem 2003; 40: 131-137.
56. Sherrer YS, Bloch DA, Mitchell DM, Young DY, Fries JF. The development of disability in rheumatoid arthritis. Arth Rheum 1986; 26: 494-500.
57. Feigenbaum SL, Masi AT, Kaplan SB. Prognosis in rheumatoid arthritis. A longitudinal study of newly diagnosed younger adult patients. Am J Med 1979; 66: 377-378.
58. Kandiah DD, Sali A, Sheng Y, Victoria EJ, Marquis DM, Coutts SM et al. Current insights into the "phospholipid" syndrome: clinical, immunological and molecular aspects. Adv Immunol 1998; 70: 507-563.
59. Hughes G. The anticardiolipin syndrome. Clin Exp Rheum 1985; 3: 285-286.
60. Hunt JE, McNeil HP, Morgan GJ, Crameri RM, Krillis SA. A phospholipid-β2-glycoprotein 1 complex is antigen for anticardiolipin antibodies occurring in autoimmune disease but not with infection. Lupus 1992; 1: 75-81.
61. Hunt JE, Simpson RJ, Krillis SA. Identification of a region of β2-glycoprotein 1 critical for lipid binding and anti-cardiolipin antibody cofactor. Pro Natl Acad Sci (USA) 1993; 90: 2141-2145.
62. Bevers EM, Galli M, Barbui T, Comfurius P, Zwaal RFA. Lupus anticoagulant IgG's (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin. Throm Haemostasis 1991; 66: 629-632.
63. Reddel SW, Krills S. Testing for and clinical significance of anticardiolipin antibodies. Clin Diag Lab Immunol 1999; 6: 775-782.
64. Amengual O, Atsumi T, Khamashta MA, Koihe T, Hughes GRV. Specificity of ELISA for antibody to β2-glycoprotein 1 in patients with antiphospholipid syndrome. Br J Rheum 1996; 35: 1239-1243.
65. Hoffman GS, Specks U. Antineutrophil cytoplasmic antibodies. Arth Rheum 1998; 41: 1521-1537.
66. Vassilpoulos D, Hoffman GS. Clinical utility of testing for antineutrophil cytoplasmic antibodies. Clin Diag Lab Immunol 1999; 6: 645-651.
67. Koldingsnes W, Gran JT, Omdal R, Husby G. Wegeners granulomatosis: long-term follow-up of patients treated with pulse cyclophosphamide. Br J Rheum 1998; 37: 659-664.
68. Merkel PA, Polisson RP, Chang Y, Skates SJ, Niles JL. Prevalence of anti-neutrophil cytoplasmic antibodies in a large inception cohort of patients with connective tissue disease. Ann Intern Med 1997; 126: 867-873.
69. Gross WL, Csernok E. Immunodiagnostic and pathophysiologic aspect of antineutrophil cytoplasmic antibodies in vasculitis. Curr Opin Rheum 1995; 7: 11-19.
70. Wiik A. Rational use of ANCA in the diagnosis of vasculitis. Rheum 2002; 41: 481-483.
71. Dispenzieri A, Gertz MA, Therneau TM, Kyle RA. Retrospective cohort study of 148 patients with polyclonal gammopathy. Mayo Clin Proc 2001; 76: 476-484.
72. Hay EM, Freemont AJ, Kay RA, Bernstein RM, Holt PJ, Pumphrey RS. Selective polyclonal increase of immunoglobulin G1 subclass: a link with Sjogren's syndrome. Ann Rheum Dis 1990; 49: 373-377.
73. Kyle RA, Child JA, Anderson K, Barolgie B, Bataille R, Bensinger R et al. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the international myeloma working group. Br J Haematol 2003; 121:749-757.
74. Kassa SS, Thomas TL, Moutsopoulos HM, Hoover R, Kimberly RP, Budman DR et al. Increased risk of lymphoma in sicca syndrome. Ann Intern Med 1978; 89: 888-892.
75. Farr M, Tunn EJ, Bacon PA, Smith DH. Hypogammaglobulinaemia and thrombocytopenia associated with sulphasalizine therapy in rheumatoid arthritis. Ann Rheum Dis 1985; 44: 723-744.
76. Snowden N, Dietch DM, The LS, Hilton RC, Haeney MR. Antibody deficiency associated with gold therapy: natural history and management in 22 patients. Ann Rheum Dis 1996; 55: 616-621.
77. Mollnes TE, Haga HJ, Brun JG, Nielsen EW, Sjoholm A, Stufeldt G et al. Complement activation in patients with systemic lupus erythematosus without nephritis. Rheum 1999; 38: 933-940.
78. Davies KA. Complement, immune complexes and systemic lupus erythematosus. Br J Rheum 1996; 35: 5-23.
79. Liszewski MK, Kahl LE, Atkinson JP. The functional role of complement genes in systemic lupus erythematosus and Sjogren's syndrome. Curr Opin Rheumatol 1989; 1: 347-352.
80. Brouet JC, Clauvel JP, Danon F. Biological and clinical significance of cryoglobulins. Am J Med 1974; 57: 775-788.
81. Cacoub P, Fabiani FL, Mussel. Mixed cryoglobulinaemia and hepatitis C virus. Am J Med 1994; 96: 124-132.
82. Speckett G. Oxford Hand Book of Clinical Immunology. Oxford (UK): Oxford Press; 1999. p. 482-489.